We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Simple, Inexpensive, Fast and Accurate Nano-Sensors Pinpoint Infectious Diseases Like SARS CoV-2

By LabMedica International staff writers
Posted on 03 Feb 2022

A novel method uses simple, inexpensive, fast and accurate nano-sensors to pinpoint infectious diseases like Ebola virus (EBOV) and SARS CoV-2. More...

The technology, developed by researchers at Arizona State University (Tempe, AZ, USA) and the University of Washington Seattle (Seattle, WA, USA), represents a significant advance in the fight against infectious diseases. It can be developed and produced at very low cost, deployed within weeks or days after an outbreak, and made available for around one cent per test.

In recent years, deadly infectious diseases, including Ebola and COVID-19, have emerged to cause widespread human devastation. Although researchers have developed a range of sophisticated methods to detect such infections, existing diagnostics face many limitations. The new technique, known as Nano2RED, is a clever twist on conventional high-accuracy tests relying on complex testing protocols and expensive readout systems. The in-solution nano-sensors (“Nano2” in the name) serve to detect disease antigens in a sample by simple mixing. The innovative Rapid and Electronic Readout process (“RED”) developed by the researchers delivers test results, which are detectable as a color change in the sample solution, and record the data through inexpensive semiconductor elements such as LEDs and photodetectors.

Compared with widely used high-accuracy lab tests, such as ELISA, Nano2RED is much easier to use. It does not require surface incubation or washing, dye labeling, or amplification, yet still provides about 10 times better sensitivity than ELISA. In addition, the use of semiconductor devices supports a highly portable digital readout system, which can be developed and produced at a cost as low as a few dollars, making it ideal not only for lab use but for clinics, home use, and remote or resource-strained locations. This approach is based on modular designs, and could potentially be used to test for any pathogen.

As a proof of concept, the researchers conducted a study to apply their innovative method to test for two prominent diseases, Ebola virus (EBOV) and SARS CoV-2. The new technology can identify secreted glycoprotein (sGP), a telltale fingerprint of Ebola virus disease and the SARS-CoV-2 spike protein receptor binding domain (RBD). Similar to ELISA, Nano2RED also relies on binding affinity for positive diagnosis but instead uses floating gold nanoparticles for readout. Unlike ELISA, Nano2RED can be developed from scratch in roughly 10 days and theoretically applicable for any pathogen, providing vitally important early surveillance in the case of a disease outbreak. It can deliver test results in 15-20 minutes and may be administered at an estimated cost of a penny per test. In the current study, the new test was shown to detect Ebola’s sGP in serum with a sensitivity roughly 10 times better than ELISA.

“This technology works not because it is complex but because it is simple,” said Chao Wang, a researcher at Arizona State University’s Biodesign Institute and School of Electrical, Computer & Energy Engineering. “Another unique feature is the multidisciplinary nature of biosensing. A fundamental understanding of biochemistry, fluidics, and optoelectronics helped us come up with something this ‘simple’.”

Related Links:
Arizona State University 
University of Washington Seattle 


Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
Collection and Transport System
PurSafe Plus®
New
Gold Member
Collection and Transport System
PurSafe Plus®
New
Capillary Blood Collection Tube
IMPROMINI M3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: GeneseeqPrime analyzes 425 cancer-related genes by next-generation sequencing (Photo courtesy of Geneseeq)

Comprehensive Tumor Profiling Kit Decentralizes and Standardizes Oncology Testing

Cancer remains one of the leading global health burdens, with accurate and timely tumor profiling critical to guiding treatment decisions. Traditional approaches often struggle to capture the full range... Read more

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Technology

view channel
Image: The sensor can help diagnose diabetes and prediabetes on-site in a few minutes using just a breath sample (Photo courtesy of Larry Cheng/Penn State)

Graphene-Based Sensor Uses Breath Sample to Identify Diabetes and Prediabetes in Minutes

About 37 million U.S. adults live with diabetes, and one in five is unaware of their condition. Diagnosing diabetes often requires blood draws or lab visits, which are costly and inconvenient.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.